The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Vakhnina N.V.

Sechenov First Moscow State Medical University

Gogoleva A.G.

Sechenov First Moscow State Medical University;
Sklifosovsky Institute of Clinical Medicine

The criteria for effectiveness of reperfusion therapy and neuroprotective therapy in ischemic stroke

Authors:

Zaharov V.V., Vakhnina N.V., Gogoleva A.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4): 86‑92

DOI: 10.17116/jnevro202112104186

Read: 3902 times

Download PDF (RU)
Contact the author
Table of contents

THE CRITERIA FOR EFFECTIVENESS OF REPERFUSION THERAPY AND NEUROPROTECTIVE THERAPY IN ISCHEMIC STROKE
THE CRITERIA FOR EFFECTIVENESS OF REPERFUSION THERAPY AND NEUROPROTECTIVE THERAPY IN ISCHEMIC STROKE

To cite this article:

Zaharov VV, Vakhnina NV, Gogoleva AG. The criteria for effectiveness of reperfusion therapy and neuroprotective therapy in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):86‑92. (In Russ.)
https://doi.org/10.17116/jnevro202112104186

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Adju­vant pharmacological modu­lation with Cyto­flavin in reha­bilitation at stages 2—3 in patients with acute cere­bral insu­fficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Diagnoctic test accu­racy of nucleated red blood cells in non-hematologic inte­nsive care patients (meta-analysis). Russian Journal of Anesthesiology and Reanimatology. 2025;(2):68-82
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
Infe­ctious diseases of the respiratory system in Irku­tsk in 2023 acco­rding to auto­psy data. Russian Journal of Archive of Pathology. 2025;(2):37-42
Pharmacological correction of burning eye syndrome. Russian Annals of Ophthalmology. 2025;(2):51-58
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Prognostic factors for progression and risk chro­nic obstructive pulmonary disease adve­rse outcomes. Journal of Respiratory Medi­cine. 2025;(2):71-78
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
The stru­cture of causes of death of the adult popu­lation of the Moscow region in 2019 and 2023. Russian Journal of Archive of Pathology. 2025;(3):40-48
Abstract:

The narrative review discusses the data on efficacy and safety of reperfusion therapy (RT) and neuroprotective therapy in ischemic stroke. The influence of therapy on mortality, residual neurologic deficit and disability is analyzed. It was shown that RT (thrombolysis or mechanical thromboextraction) leads to significant decrease of residual neurologic deficit or disability. The influence of RT on mortality is controversial. There is some evidence that RT can increase early mortality due to hemorrhagic complications. Neuroprotective therapy is much less studied in stroke but is recognized as safe. Neuroprotective therapy (i.e. cerebrolysin) can diminish residual neurologic deficit and disability, while it has no influence on mortality.

Keywords:

ischemic stroke
reperfusion therapy
thrombolysis
mechanical thromboextraction
neuroprotective therapy
cerebrolysin
efficacy
mortality

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Vakhnina N.V.

Sechenov First Moscow State Medical University

Gogoleva A.G.

Sechenov First Moscow State Medical University;
Sklifosovsky Institute of Clinical Medicine

Received:

11.02.2021

Accepted:

04.03.2021

Close metadata

References:

  1. Polikarpov AV, Aleksandrova GA, Golubev NA, et al. The incidence of entire population in Russia in 2017. Statistical materials. (In Russ.). https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god
  2. Shamalov NA. Reperfusion therapy for ischemic stroke in the Russian Federation: Problems and promises. Neurology, Neuropsychiatry, Psychosomatics. 2014;(2S):15-21. (In Russ.).
  3. Gusev EI, Martynov MYu, Yasamanova AA, et al. Thrombolytic therapy of ischemic stroke. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. Special ISSUES. 2018;118(12):4-14. (In Russ.). https://doi.org/10.17116/jnevro20181181224
  4. Gusev EI, Scvorzova VI. Ischemia golovnogo mozga. M.: Medicine; 2001. (In Russ.).
  5. Alasheev AM, Belkin AA, Voznyuk IA, et al. Clinical guidelines for thrombolytic therapy in patients with ischemic stroke. M. 2015. (In Russ.).
  6. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;2014(7):CD000213. Published 2014 Jul 29.  https://doi.org/10.1002/14651858.CD000213.pub3
  7. Prabhakaran S, Ruff I, Bernstein R. Acute stroke intervention: a systematic review. JAMA. 2015;313:14:1451-1462. https://doi.org/10.1001/jama.2015.3058
  8. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Hacke W. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. The Lancet. 2010;375(9727):1695-1703. https://doi.org/10.1016/s0140-6736(10)60491-6
  9. Pizova NV. Thrombolytic therapy for ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2013;3:55-59. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2342
  10. Shamalov NA. Reperfusion therapy for acute ischemic stroke. Effective Pharmacotherapy. 2014;31(3):54-57. (In Russ.).
  11. Lisboa RS, Jovanovic BD, Albert MJ. Analysis of the safety and efficacy of intra-arterial trombolytic therapy in ischemic stroke. Stroke. 2002;33:2866-2871. https://doi.org/10.1161/01.STR.0000038987.62325.14
  12. Nam J, Jing H, O’Reilly D. Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis. Int J Stroke. 2015;10(1):13-22. Epub 2013 Jan 7. PMID: 23294872. https://doi.org/10.1111/j.1747-4949.2012.00914.x
  13. Kulesh AA. The modern concept of neuroprotective therapy in the acute period of ischemic stroke. Meditsinskiy Sovet. 2020;11:82-91. (In Russ.). https://doi.org/10.21518/2079-701X-2020-11-82-91
  14. Tsivgoulis G, Katsanos AH, Schellinger PD, et al. Successful reperfusion with intravenous thrombolysis preceding mechanical thrombectomy in large vessel occlusions. Stroke. 2018;49:2325. https://doi.org/10.1161/STROKEAHA.117.019261
  15. Goyal M, Demchuk AM, Bijoy KM, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019- 30.  https://doi.org/10.1056/NEJMoa1414905
  16. Powers WJ, Derdain CP, Biler J, et al. 2015 American Heart Association/American Stroke Association Focus Update of 2013 Guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment. A guideline for healthcare professionals from the American Heart Association American Stroke Association. Stroke. 2015;46:3024-3039. https://doi.org/10.1161/STR.0000000000000074
  17. Ueda H, Fujita R. Cell death mode switch from necrosis to apoptosis in brain. Biol Pharm Bull. 2004;27(7):950.  https://doi.org/10.1248/bpb.27.950
  18. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79(4):1431. https://doi.org/10.1152/physrev.1999.79.4.1431
  19. Wu QJ, Tymianski M. Targeting NMDA receptors in stroke: new hope in neuroprotection. Molecular Brain. 2018;11:15.  https://doi.org/10.1186/s13041-018-0357-8
  20. Caplan LR. Caplan’s Stroke: A Clinical Approach, 4th ed, Saunders Elsevier; Philadelphia: 2009. Basic pathology, anatomy, and pathophysiology of stroke. p. 22. 
  21. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157-188.  https://doi.org/10.1016/j.pneurobio.2013.11.006
  22. Hannan MA, Dash R, Sohag AAM, Haque MN, Moon IS. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020;13:116.  https://doi.org/10.3389/fnmol.2020.00116
  23. Chamorro A, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15(8):869-881.  https://doi.org/10.1016/S1474-4422(16)00114-9
  24. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69(5):576.  https://doi.org/10.1001/archneurol.2011.3590
  25. Kollikowski AM, Schuhmann MK, Nieswandt B, et al. Local Leukocyte Invasion during Hyperacute Human Ischemic Stroke. Ann Neurol. 2020;87(3):466.  https://doi.org/10.1002/ana.25665
  26. Xiong XY, Liu L, Yang QW. Refocusing Neuroprotection in Cerebral Reperfusion Era: New Challenges and Strategies. Front Neurol. 2018;9:249.  https://doi.org/10.3389/fneur.2018.00249
  27. Anzell AR, Maizy R, Przyklenk K, Sanderson TH. Mitochondrial quality control and disease: Insights into ischemia reperfusion injury. Mol Neurobiol. 2018;55:2547-64.  https://doi.org/10.1007/s12035-017-0503-9
  28. Luxitaa G, Satyanarayana CRU, Kumar SS, George M. Neuroprotective agents in Acute Ischemic Stroke — A Reality Check. Biomed Pharmacother. 2019;109:2539-2547. https://doi.org/10.1016/j.biopha.2018.11.041
  29. Lampl Y, Gilad R, Geva D, et al. Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. Clin Neuropharmacol. 2001;24(1):11-15.  https://doi.org/10.1097/00002826-200101000-00003
  30. Afshari D, Moradian N, Rezaei M. Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clin Neurol Neurosurg. 2013;115(4):400-404.  https://doi.org/10.1016/j.clineuro.2012.06.001
  31. Muir KW, Lees KR, Ford I, et al. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet Lond Engl. 2004;363(9407):439-445.  https://doi.org/10.1016/S0140-6736(04)15490-1
  32. Saver JL, Starkman S, Eckstein M, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372(6):528-536.  https://doi.org/10.1056/NEJMoa1408827
  33. Naritomi H, Moriwaki H, Metoki N, et al. Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. Drugs RD. 2010;10(3):155-163.  https://doi.org/10.2165/11586550-000000000-00000
  34. Mitta M, Goel D, Bansal KK, et al. Edaravone — citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012;60:36-38. 
  35. Secades JJ, Alvarez-Sabin J, Castillo J, et al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
  36. Dávalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet Lond Engl. 2012;380(9839):349-357.  https://doi.org/10.1016/S0140-6736(12)60813-7
  37. Chen H, Tung YC, Li B, et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiology of Aging. 2007;28(8):1148-11623. https://doi.org/10.1016/j.neurobiolaging.2006.05.036
  38. Gromova OA, Torshin IYu, Zgoda VG, Tikhonova OV. Oligopeptide membrane fraction of Cerebrolysine. Journal of Neurology and Psychiatry. 2006;7:68-70. (In Russ.). https://doi.org/10.17116/jnevro201911908175
  39. Gromova OA, Torshin IYu, Gogoleva IV. Mechanisms of neurotrophic and neuroprotective action of cerebrolysin in cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova (Sp). 2014;114(3):43-50. (In Russ.). https://doi.org/10.21518/2079-701X-2020-8-36-45
  40. Gromova OA, Torshin IYu, Stakhovskaia LV, et al. On comparative studies of neurotrophic preparations based on brain hydrolysates. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119(10):134-140. (In Russ.). https://doi.org/10.17116/jnevro2019119101134
  41. Zhang C, Chop M, Cui Y, et al. Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke. Journal of Neuroscience Research. 2010;88:3275-3281. https://doi.org/10.1002/jnr.22495
  42. Skvortsova VI, Stakhovskaia LV, Gubskiĭ LV, et al. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2004;(suppl 11):51-55. (In Russ.). PMID: 15559222.
  43. Shamalov NA, Stakhovskaia LV, Burenchev DV, et al. The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2010;110(12 Pt 2):34-37. (In Russ.). PMID: 21626816.
  44. Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 2017;10(3):153-160. 
  45. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. Cerebrolysin in patients with acute ischemic stroke in Asia. Stroke. 2012;43(3):630-636.  https://doi.org/10.1161/STROKEAHA.111.628537
  46. Lang W, Stadler CH, Poljakovic Z, Fleet D. A Prospective, Randomized, Placebo-Controlled, Double-Blind Trial about Safety and Efficacy of Combined Treatment with Alteplase (rt-PA) and Cerebrolysin in Acute Ischaemic Hemispheric Stroke. International Journal of Stroke. 2013;8(2):95-104.  https://doi.org/10.1111/j.1747-4949.2012.00901.x
  47. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y. Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatr Dis Treat. 2014;10:2299. https://doi.org/10.2147/NDT.S75304
  48. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159.  https://doi.org/10.1161/STROKEAHA.115.009416
  49. Guekht A, Heiss D, Gusev E, Vester J, Doppler E, Muresanu D. Cerebrolysin and recovery after stroke (CARS 2): a randomized, placebo-controlled, double-blind, multicenter clinical study. J Neurol Sci. 2015;357:e103. https://doi.org/10.1016/j.jns.2015.08.336
  50. Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H. Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med. 2016;11(5):2015-2020. https://doi.org/10.3892/etm.2016.3139
  51. Ladurner G, Kalvach P, Moessler H. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transmission. 2005;112(3):415-428.  https://doi.org/10.1007/s00702-004-0248-2
  52. Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640.  https://doi.org/10.1007/s10072-017-3214-0
  53. Ziganshina LE, Abakumova T, Hoyle CHV. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2020;7:CD007026. https://doi.org/10.1002/14651858.CD007026.pub6
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.